Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.53 |
| ▸ | AHR | P35869 | 3/20 | 0.52 |
| ▸ | CMA1 | P23946 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736936 | 0.85 | CA12 (0.56) | ESR1AHRCYP19A1HTR6CYP2A6 | |
| SCHEMBL1035515 | 0.85 | CA12 (0.56) | ESR1AHRCYP19A1HTR6CYP2A6 | |
| SCHEMBL516614 | 0.81 | CA1 (0.60) | ESR1AHRCMA1CYP19A1HTR6 | |
| SCHEMBL31497301 | 0.81 | CA1 (0.60) | ESR1AHRCMA1CYP19A1HTR6 | |
| SCHEMBL1120379 | 0.81 | TYR (0.52) | ESR1AHRCMA1CYP19A1HTR6 | |
| SCHEMBL30260844 | 0.81 | ESR1 (0.53) | ESR1AHRCMA1CYP19A1HTR6 | |
| SCHEMBL1144770 | 0.81 | ESR1 (0.53) | ESR1AHRCMA1CYP19A1HTR6 | |
| Hydrochloric Acid SCHEMBL5241443 | 0.79 | CA1 (0.58) | ESR1AHRCMA1CYP19A1HTR6 | |
| Hydrochloric Acid SCHEMBL28101627 | 0.79 | TYR (0.50) | ESR1AHRCMA1CYP19A1HTR6 | |
| SCHEMBL25195372 | 0.77 | ESR1 (0.46) | ESR1AHRCMA1CYP19A1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240285614-A1 | PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230322672-A1 | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES | VIEWPOINT THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322672-A1 | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES | VIEWPOINT THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2022047315-A1 | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES | VIEWPOINT THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-110036004-A | Inhibitors of cyclin dependent kinase 7(CDK7) | 希洛斯医药品股份有限公司 | 2019-07-19 | — | — | CN | disclosed |
| EP-2294051-A1 | ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM | Boehringer Ingelheim International GmbH (DE) | 2011-03-16 | — | — | EP | disclosed |
| EP-2276731-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | Boehringer Ingelheim International GmbH (DE) | 2011-01-26 | — | — | EP | disclosed |
| EP-2265589-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | Abbott Healthcare Products B.V. (NL) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009142984-A1 | ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009126675-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126675-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009115515-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-09-24 | — | — | WO | disclosed |
| EP-1869010-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007008146-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006108709-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322672-A1 | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES | CRYAB, CRYZ, PDE6C | ESR1 4466/4885AHR 1339/4885CMA1 4130/4885 |
| US-20240285614-A1 | PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM2B, RRM2, RRM1 | ESR1 1899/4885AHR 932/4885CMA1 2766/4885 |
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | ESR1 2320/4885AHR 1519/4885CMA1 1593/4885 |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | ESR1 2320/4885AHR 1519/4885CMA1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.